Sivik Global Healthcare LLC Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sivik Global Healthcare LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,500 shares of the pharmaceutical company’s stock after purchasing an additional 40 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 2.1% of Sivik Global Healthcare LLC’s portfolio, making the stock its 29th largest position. Sivik Global Healthcare LLC’s holdings in Vertex Pharmaceuticals were worth $5,086,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Hartford Funds Management Co LLC raised its position in Vertex Pharmaceuticals by 7.7% in the 4th quarter. Hartford Funds Management Co LLC now owns 890 shares of the pharmaceutical company’s stock valued at $362,000 after purchasing an additional 64 shares in the last quarter. Savant Capital LLC boosted its holdings in Vertex Pharmaceuticals by 30.5% in the fourth quarter. Savant Capital LLC now owns 2,671 shares of the pharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 624 shares in the last quarter. Mission Wealth Management LP raised its holdings in Vertex Pharmaceuticals by 4.5% during the fourth quarter. Mission Wealth Management LP now owns 4,893 shares of the pharmaceutical company’s stock worth $1,991,000 after purchasing an additional 212 shares in the last quarter. Certuity LLC lifted its position in shares of Vertex Pharmaceuticals by 20.2% during the 4th quarter. Certuity LLC now owns 2,580 shares of the pharmaceutical company’s stock worth $1,050,000 after buying an additional 433 shares during the last quarter. Finally, Norden Group LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $250,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Stock Down 0.9 %

Shares of VRTX stock traded down $3.39 during mid-day trading on Tuesday, reaching $392.81. 1,727,899 shares of the company were exchanged, compared to its average volume of 1,226,496. The company has a market capitalization of $101.53 billion, a P/E ratio of 28.28, a P/E/G ratio of 1.87 and a beta of 0.35. The business’s 50 day simple moving average is $410.52 and its 200 day simple moving average is $399.52. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $320.01 and a fifty-two week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period in the previous year, the company earned $3.33 earnings per share. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. HC Wainwright upped their price objective on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 20th. Sanford C. Bernstein cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Finally, UBS Group cut their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.